๐Ÿ“ก TrialSonar Radar Report ยท 18 Nov 2026 โฑ 41 Phase 3 readouts due in the next 14 days (131 in 30): โ€ข 2026-11-18 โ€” POETYK SjS-1 (Bristol-Myers Squibb $BMY, Immuno) โ€ข 2026-11-18 โ€” Drugs-SNPs (Medicine Invention Design, Inc, Oncology) โ€ข 2026-11-20 โ€” Pembrolizumab (Merck Sharp & Dohme LLC $MRK, Oncology) โ€ข 2026-11-21 โ€” Cabergoline tablets (Changchun GeneScience Pharmaceutical Co., Ltd., Cardio-Met) โ€ข 2026-11-23 โ€” Investigational varicella vaccine (GlaxoSmithKline $GSK, Infectious) ๐Ÿ” Registry changes this week: โ€ข Nogapendekin alfa inbakicept (NAI) (ImmunityBio, Inc.): Not yet recruiting โ†’ Withdrawn โ€ข NMS-03305293 (Nerviano Medical Sciences): Active, not recruiting โ†’ Terminated โ€ข AB-3028 (Arsenal Biosciences, Inc.): Active, not recruiting โ†’ Terminated โ€ข Debio 4326 (Debiopharm International SA): readout 2026-10 โ†’ 2026-10-09 (+0.3 mo) ๐Ÿ“‰ Delay Index: 46% of active trials (registered >1 yr ago) have pushed their readout >6 months. Most often late: Acerta Pharma BV 91%, Ionis Pharmaceuticals, Inc. 83%, Taiho Oncology, Inc. 70% โš• FDA: KLYGEFA approved (ALEXION PHARM); PEBRILZO approved (BIOCON BIOLOGICS INC) Full report & live map: https://trialsonar.pages.dev/report/ Data: ClinicalTrials.gov, openFDA, fda.gov. Not investment advice.